MONROVIA, Calif.--(BUSINESS WIRE)--Feb. 6, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in two upcoming conferences:

• Guggenheim Healthcare Talks Forum | Oncology Day
  Date: Thursday, February 13, 2020
  Location: New York
  Presentation Time: 9:00 a.m. EST
• 9^th Annual SVB Leerink Global Healthcare Conference
  Date: Wednesday, February 26, 2020
  Location: New York
  Presentation Time: 11:00 a.m. EST

Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 15 candidates engineered with Xencor's XmAb^® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005937/en/

Source: Xencor, Inc.

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com